Results 21 to 30 of about 277,689 (315)

Role of raloxifene in the management of postmenopausal osteoporosis of rheumatoid arthritis patients

open access: yesEuropean Pharmaceutical Journal, 2023
Due to the severe side effects of long-term treatment using hormone replacement therapy, Raloxifene (RLX) is introduced with beneficial effects on rheumatoid arthritis (RA) for postmenopausal women.
Salari M.   +3 more
doaj   +1 more source

Vaccination For Patients With Rheumatic Diseases In The Era Of Biologics [PDF]

open access: yes, 2018
A large proportion of patients with rheumatic disease have an immunocompromised status resulting from disease pathogenesis itself and/or several immunosuppressive drugs including biologics.
한상훈
core   +1 more source

Vitamin E and Autoimmune Diseases: A Narrative Review [PDF]

open access: yesReviews in Clinical Medicine, 2018
Autoimmune diseases are characterized by the attack of the immune system to normal tissues. Patients with autoimmune diseases usually have the deficiency of dietary factors  that may be related to the etiology of these conditions.
Zahra Rezaieyazdi   +3 more
doaj   +1 more source

Cardiovascular disease in rheumatic diseases

open access: yesTerapevticheskii arkhiv, 2016
The representatives of immunoinflammatory diseases are rheumatic ones, such as primarily rheumatoid arthritis, juvenile idiopathic arthritis, spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, and other systemic connective diseases, which are characterized by a high risk for untimely death.
E L Nasonov, T V Popkova, D S Novikova
openaire   +3 more sources

Validation of the educational needs assessment tool as a generic instrument for rheumatic diseases in seven European countries [PDF]

open access: yes, 2013
Objectives To validate the educational needs assessment tool (ENAT) as a generic tool for assessing the educational needs of patients with rheumatic diseases in European Countries.
Tennant, Alan   +58 more
core   +1 more source

Sustained Drug Free Remission of Lupus Panniculitis with Methotrexate: A Report From Nepal

open access: yesJournal of Nepal Medical Association, 2018
Cutaneous manifestations are second most common presenting feature of lupus. Discoid lupus erythematosus is the most common variant amongst all; lupus panniculitis being described in only 2-5% of cases.
Binit Vaidya   +3 more
doaj   +1 more source

Social implications of rheumatic diseases [PDF]

open access: yes, 2016
Social consequences of a disease constitute limitations in performing roles relating to working life as well as family and social life caused by the disease, mainly chronic.
Filip Raciborski   +2 more
core   +1 more source

Rituximab used for simultaneous treatment of PR3‐ANCA positive vasculitis associated with rheumatoid arthritis: A case report

open access: yesClinical Case Reports, 2020
We treated PR3‐ANCA positive vasculitis in a patient diagnosed with rheumatoid arthritis using rituximab. Monoclonal antibody therapy can be used to simultaneous treat more than one collagen disease in such patients.
Akihiro Yamada   +2 more
doaj   +1 more source

Increased risk of malignancy in patients with systemic lupus erythematosus: population-based cohort study in Korea

open access: yesArthritis Research & Therapy, 2021
Background This study aimed to evaluate the crude incidence rates and relative risk of malignancy in Korean patients with SLE. Methods We conducted a retrospective nationwide cohort study using databases from the National Health Insurance Service in ...
Jung-Yong Han   +5 more
doaj   +1 more source

Reduced Humoral Response of SARS-CoV-2 Antibodies following Vaccination in Patients with Inflammatory Rheumatic Diseases—An Interim Report from a Danish Prospective Cohort Study

open access: yesVaccines, 2021
Background/Purpose: In light of the current COVID-19 pandemic, whether patients with rheumatic musculoskeletal disease (RMD) treated with conventional (cs) or biologic (b) disease-modifying drugs (DMARDs) exhibit an adequate immune response to the ...
Karen Schreiber   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy